CLINICAL_TRIALS
trial_result
· 2021-01-28
Clinical Trial Update: LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia [Phase 2]
Summary
Phase 2 clinical trial update for LBH589 in Waldenström's macroglobulinemia has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Dana-Farber Cancer Institute | Conditions: Waldenstrom's Macroglobulinemia | Phase 2 | Status: COMPLETED | Results posted: 2021-01-28